Last reviewed · How we verify
NCT07503587: PPF
Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis
Phase 3 trial testing HSK44459 in Progressive Pulmonary Fibrosis in 378 participants. Not yet recruiting.
30 December 2028
Quick facts
| Lead sponsor | Haisco Pharmaceutical Group Co., Ltd. |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 378 |
| Start date | 5 April 2026 |
| Primary completion | 30 December 2028 |
| Estimated completion | 1 March 2029 |
Drugs / interventions tested
- HSK44459 — full drug profile →
- Placebo
Conditions studied
- Progressive Pulmonary Fibrosis — all drugs for Progressive Pulmonary Fibrosis →
Sponsor
Haisco Pharmaceutical Group Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with Progressive Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is open to adults with PPF . The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07503587
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HSK44459
Trials testing the same drug.
- NCT07519070 — A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44 · Phase 3 · not yet recruiting
- NCT07019090 — Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · not yet recruiting
- NCT06996912 — A Study for HSK44459 in Participants With Atopic Dermatitis · Phase 2 · active not recruiting
- NCT06902428 — Evaluating the Efficacy and Safety of of HSK44459 in Patients With Behçet's Disease · Phase 2 · not yet recruiting
- NCT06858657 — A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK44459 in Healthy Subjects · Phase 1 · completed
Other recruiting trials for Progressive Pulmonary Fibrosis
Currently open trials in the same condition.
- NCT07486206 — Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial · NA · recruiting
- NCT07466420 — Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases. · NA · recruiting
- NCT07269262 — SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers · NA · recruiting
- NCT06951217 — An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) · Phase 2 · recruiting
- NCT06238622 — A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Pr · Phase 3 · recruiting
Other Haisco Pharmaceutical Group Co., Ltd. trials
Trials by the same sponsor.
- NCT07533786 — A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdomina · Phase 2 · not yet recruiting
- NCT07519070 — A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44 · Phase 3 · not yet recruiting
- NCT07521345 — A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and the Food Effect of HSK55879 Tablets in Healt · Phase 1 · recruiting
- NCT07335055 — A Study for HSK47388 in Participants With Ulcerative Colitis · Phase 2 · recruiting
- NCT07363460 — Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07503587 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Haisco Pharmaceutical Group Co., Ltd.
- Last refreshed: 31 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07503587.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing